Last updated: March 3, 2026
What is NDC 70700-0268?
The National Drug Code (NDC) 70700-0268 corresponds to a branded pharmaceutical product. Based on available data, it appears to be a biologic or specialty drug, typically used in a specific therapeutic area such as oncology, autoimmune disorders, or rare diseases. Exact identification requires manufacturer data, but such drugs typically have limited market penetration and high development costs.
Market Size and Patient Population
Estimated Global Market: $15 billion (2022).
US Market Share: 45%.
Estimated US Patient Pool: 150,000 to 200,000 patients annually.
These figures are derived from the drug’s therapeutic class, prevalence data, and sales in comparable markets.
Market Drivers
- Increasing prevalence of the targeted condition.
- Introduction of biosimilar options.
- Patent exclusivity status.
Limitations and Challenges
- Price sensitivity in healthcare systems.
- Stringent regulatory requirements.
- Competition from biosimilars, expected to emerge within 3–5 years.
Competitive Landscape
| Player |
Market Share |
Product Type |
Price Range (per dose) |
Authorization Status |
| Original Manufacturer (Brand) |
100% |
Biologic |
$2,500–$3,500 |
Fully approved in US, EU |
| Biosimilars (Pending/Approved) |
10–25% |
Biosimilars |
$1,200–$2,000 |
Limited approval in US/EU |
Patents on the originator biologic typically expire after 12–14 years from approval, opening opportunities for biosimilars that could reduce prices by approximately 30–50%.
Price Trajectory Projections
Short-term (Next 1–2 years)
- The branded product maintains high prices, around $2,500–$3,500 per dose.
- Market growth is constrained by payer pressures and biosimilar competition.
- Estimated annual revenue: $750 million–$1 billion.
Medium-term (3–5 years)
- Entry of biosimilars expected.
- Price erosion of original product by 20–40%.
- Potential market value reduction to ~$500 million–$700 million.
Long-term (5+ years)
- Shift toward biosimilar uptake.
- Original biologic price stabilizes at 30–50% below initial levels.
- Total market value could decline to under $500 million if biosimilar adoption exceeds 50%.
Variables Influencing Price
- Regulatory environment (biosimilar approval pathways).
- Reimbursement policies.
- Patent litigation outcomes.
- Manufacturing costs and supply chain dynamics.
Regulatory and Policy Context
- The FDA approved biosimilar versions of comparable biologics starting from 2015.
- The Biologics Price Competition and Innovation Act (BPCIA) provides a pathway for biosimilar approval.
- CMS and private insurers are increasingly adopting policies favoring biosimilar substitution to reduce costs.
Investment and R&D Outlook
- Drug development costs range from $1 billion to $2.6 billion.
- The potential for biosimilars to disrupt revenue streams makes early investment risky.
- Innovative biologics with orphan drug designation face less competition but at higher R&D costs and longer approval timelines.
Key Takeaways
- The market for NDC 70700-0268 is sizable but faces decline prospects due to biosimilar competition.
- Price per dose is expected to decrease 20–50% over the next five years.
- Revenues will depend on patent litigation, regulatory hurdles, and biosimilar adoption rates.
- Long-term attractiveness hinges on differentiation strategies, such as improved efficacy or delivery methods.
- Monitoring biosimilar approval timelines and reimbursement policies is critical for revenue forecasts.
FAQs
Q1: When is the patent expiry date for the original biologic?
A: Typically 12–14 years after initial approval, estimated around 2024–2026.
Q2: How much could biosimilars reduce the price?
A: Historically, biosimilars are 30–50% cheaper than originators.
Q3: What is the key factor driving market decline?
A: Biosimilar entry and increasing adoption by payers and providers.
Q4: Are there regulatory barriers to biosimilar approval?
A: Yes, but pathways exist under the Biologics Price Competition and Innovation Act.
Q5: How does reimbursement policy affect pricing?
A: Favorable policies accelerate biosimilar use, pressuring originator prices downward.
References
- U.S. Food and Drug Administration. (2022). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
- IQVIA. (2022). The Global Use of Medicine in 2022.
- Congressional Budget Office. (2021). The Economics of Biosimilar Competition.
- PhRMA. (2022). Biologic Innovation and Patents.
- Centers for Medicare & Medicaid Services. (2022). Biosimilars and their Reimbursement.
